Kasi, A., Al-Rajabi, R. M. T., Phadnis, M. A., Baranda, J. C., Li, H., Crane, G. J., Flanagan, J. R., Satelli, D., Carroll, E., Belcher, C., Bradbury, S., Roth, M. T., Kumer, S., Schmitt, T., King, C., Olyaee, M., Rastogi, A., Hejazi, R., Clark, L., Sun, W. (2026). A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.730